Novel drug targeting delivery adjuvant

Abstract

The invention provides a novel drug targeting delivery adjuvant which is at least one of pentose, hexose, sugar alcohol and disaccharide, wherein the pentose is selected from at least one of xylose and arabinose; the hexose is selected from at least one of glucose, galactose, fructose and mannose; the disaccharide is selected from at least one of sucrose, lactose, maltose and mycose; the sugar alcohol is selected from at least one of sorbitol, mannitol, erythritol, maltitol, lactitol and xylitol. Furthermore, the invention provides an application of the novel drug targeting delivery adjuvant in drug delivery, especially in targeting delivery of antisense oligodeoxynucleotide drugs PMO, PNA, 2'ome RNA (Ribonucleic Acid), peptide-PMO and siRNAs as well as macromolecular plasmids. The adjuvant has a good targeting delivery effect, and is capable of remarkably enhancing the acting effect of a drug in a target tissue; the adjuvant, which is extracted from natural products, namely saccharides, is high in clinical safety index, basically free from hurt to human body, and low in or free from toxic and side effects.

Description

technical field [0001] The invention belongs to the field of life science and drug carrier. Background technique [0002] The targeted delivery efficiency of drugs is an important factor in determining the efficacy of drugs. The methods commonly used to optimize gene therapy drugs now include: optimizing the structure of the drug itself; using macromolecular polymers as transport carriers, the most common of which are nanomaterials; The use of tissue-targeting peptides, which covalently bind peptides to drugs. [0003] Among them, drug carriers are the most widely used, but the shortcomings of existing drug delivery carriers are: [0004] 1. Targeted transport efficiency is low; [0005] 2. There is potential harm to the human body. [0006] Take Duchenne muscular dystrophy as an example. Duchenne muscular dystrophy is a fatal neuromuscular disorder linked to human X chromosome inheritance. The incidence rate in newborn boys is 1:3500. consumption and degradation. If no...

AI Technical Summary

Problems solved by technology

[0004] 1. Targeted transport efficiency is low;

[0005] 2. Potential harm to human body

[0011] However, the results of clinical tests and preclinical studies have shown that the low transport efficiency of the system is an urgent problem to be solved for various gene therapy drugs including antisense oligonucleotides, and the level of drug transport efficiency determines its therapeutic effect One of the key factors is also the bottleneck of current gene therapy

Images